Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1998 Feb;78(2):148–151. doi: 10.1136/adc.78.2.148

Oestrogen treatment of constitutional tall stature: a risk-benefit ratio

E Weimann 1, S Bergmann 1, H Bohles 1
PMCID: PMC1717477  PMID: 9579157

Abstract

Oestrogens are given in high doses for the treatment of tall stature in girls. The aim of this study was to obtain data considering efficiency, side effects, and acceptance of the treatment of 50constitutionally tall girls treated with conjugated oestrogens (7.5-11.25 mg/day). The mean (SD) adult height predictions were 188.3 (4.4) cm and the achieved height was 5.2 (3.3) cm less than the predicted height. A greater reduction from final predicted height occurred when treatment was started at an early bone age (<13.0 years) and with a remaining growth potential of greater than 10 cm. Even postmenarcheal girls, however, had a mean reduction of 4.8 (3.2) cm. The main side effects were considerable weight gain (>10 kg), an increase in triglyceride concentrations (37.5% of the patients), and increased platelet aggregation (60% of the patients). Altogether 84.6% of the patients were satisfied with the treatment and 15.4% regretted having had it.



Full Text

The Full Text of this article is available as a PDF (104.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen H., Jacobsen B. B., Kastrup K. W., Krabbe S., Peitersen B., Petersen K. E., Thamdrup E., Wichmann R. Treatment of girls with excessive height prediction. Follow-up of forty girls treated with intramuscular estradiol and progesterone. Acta Paediatr Scand. 1980 May;69(3):293–297. doi: 10.1111/j.1651-2227.1980.tb07081.x. [DOI] [PubMed] [Google Scholar]
  2. BAYLEY N., PINNEAU S. R. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr. 1952 Apr;40(4):423–441. doi: 10.1016/s0022-3476(52)80205-7. [DOI] [PubMed] [Google Scholar]
  3. Bartsch O., Weschke B., Weber B. Oestrogen treatment of constitutionally tall girls with 0.1 mg/day ethinyl oestradiol. Eur J Pediatr. 1988 Jan;147(1):59–63. doi: 10.1007/BF00442613. [DOI] [PubMed] [Google Scholar]
  4. Bierich J. R. Estrogen treatment of girls with constitutional tall stature. Pediatrics. 1978 Dec;62(6 Pt 2):1196–1201. [PubMed] [Google Scholar]
  5. Blombäck M., Hall K., Ritzén E. M. Estrogen treatment of tall girls: risk of thrombosis? Pediatrics. 1983 Sep;72(3):416–419. [PubMed] [Google Scholar]
  6. Breddin K., Grun H., Krzywanek H. J., Schremmer W. P. Zur Messung der "spontanen" Thrombocytenaggregation. Plättchenaggregationstest III. Methodik. Klin Wochenschr. 1975 Jan 15;53(2):81–89. doi: 10.1007/BF01482713. [DOI] [PubMed] [Google Scholar]
  7. Böttiger L. E., Boman G., Eklund G., Westerholm B. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet. 1980 May 24;1(8178):1097–1101. doi: 10.1016/s0140-6736(80)91550-0. [DOI] [PubMed] [Google Scholar]
  8. CLAUSS A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957 Apr;17(4):237–246. doi: 10.1159/000205234. [DOI] [PubMed] [Google Scholar]
  9. Carr M. E., Jr, Steingold K. A., Zekert S. L. Protein S levels during the normal menstrual cycle and during estrogen therapy for premature ovarian failure. Am J Med Sci. 1993 Oct;306(4):212–217. doi: 10.1097/00000441-199310000-00002. [DOI] [PubMed] [Google Scholar]
  10. Conte F. A., Grumbach M. M. Estrogen use in children and adolescents: a survey. Pediatrics. 1978 Dec;62(6 Pt 2):1091–1097. [PubMed] [Google Scholar]
  11. Crawford J. D. Treatment of tall girls with estrogen. Pediatrics. 1978 Dec;62(6 Pt 2):1189–1195. [PubMed] [Google Scholar]
  12. Davies J. A. The pre-thrombotic state. Clin Sci (Lond) 1985 Dec;69(6):641–646. doi: 10.1042/cs0690641. [DOI] [PubMed] [Google Scholar]
  13. GOLDZIEHER M. A. Treatment of excessive growth in the adolescent female. J Clin Endocrinol Metab. 1956 Feb;16(2):249–252. doi: 10.1210/jcem-16-2-249. [DOI] [PubMed] [Google Scholar]
  14. Gerstman B. B., Piper J. M., Freiman J. P., Tomita D. K., Kennedy D. L., Ferguson W. J., Bennett R. C. Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism. Int J Epidemiol. 1990 Dec;19(4):931–936. doi: 10.1093/ije/19.4.931. [DOI] [PubMed] [Google Scholar]
  15. Grüters A., Heidemann P., Schlüter H., Stubbe P., Weber B., Helge H. Effect of different oestrogen doses on final height reduction in girls with constitutional tall stature. Eur J Pediatr. 1989 Oct;149(1):11–13. doi: 10.1007/BF02024324. [DOI] [PubMed] [Google Scholar]
  16. Helmrich S. P., Rosenberg L., Kaufman D. W., Strom B., Shapiro S. Venous thromboembolism in relation to oral contraceptive use. Obstet Gynecol. 1987 Jan;69(1):91–95. [PubMed] [Google Scholar]
  17. Inman W. H., Vessey M. P., Westerholm B., Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Br Med J. 1970 Apr 25;2(5703):203–209. doi: 10.1136/bmj.2.5703.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. BMJ. 1993 Apr 10;306(6883):956–963. doi: 10.1136/bmj.306.6883.956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  20. Meade T. W. Oral contraceptives, clotting factors, and thrombosis. Am J Obstet Gynecol. 1982 Mar 15;142(6 Pt 2):758–761. doi: 10.1016/s0002-9378(16)32484-x. [DOI] [PubMed] [Google Scholar]
  21. Meade T. W., Stirling Y., Wilkes H., Mannucci P. M. Effects of oral contraceptives and obesity on protein C antigen. Thromb Haemost. 1985 Apr 22;53(2):198–199. [PubMed] [Google Scholar]
  22. Melissari E., Kakkar V. V. The effects of oestrogen administration on the plasma free protein S and C4b-binding protein. Thromb Res. 1988 Mar 1;49(5):489–495. doi: 10.1016/s0049-3848(98)90006-8. [DOI] [PubMed] [Google Scholar]
  23. Muntean W., Borkenstein M. Haemostatic changes in tall girls treated with high doses of ethinyloestradiol. Eur J Pediatr. 1980 Sep;134(3):245–248. doi: 10.1007/BF00441480. [DOI] [PubMed] [Google Scholar]
  24. Normann E. K., Trygstad O., Larsen S., Dahl-Jørgensen K. Height reduction in 539 tall girls treated with three different dosages of ethinyloestradiol. Arch Dis Child. 1991 Nov;66(11):1275–1278. doi: 10.1136/adc.66.11.1275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Prader A., Zachmann M. Treatment of excessively tall girls and boys with sex hormones. Pediatrics. 1978 Dec;62(6 Pt 2):1202–1210. [PubMed] [Google Scholar]
  26. Reeser H. M., Heremans G. F., van Gelderen H. H. Reduction of adult height in tall girls. Eur J Pediatr. 1979 Sep;132(1):37–41. doi: 10.1007/BF00443202. [DOI] [PubMed] [Google Scholar]
  27. Reeve E. B. Steady state relations between factors X, Xa, II, IIa, antithrombin III and alpha-2 macroglobulin in thrombosis. Thromb Res. 1980 Apr 1;18(1-2):19–31. doi: 10.1016/0049-3848(80)90167-x. [DOI] [PubMed] [Google Scholar]
  28. Vin F., Allaert F. A., Levardon M. Influence of estrogens and progesterone on the venous system of the lower limbs in women. J Dermatol Surg Oncol. 1992 Oct;18(10):888–892. doi: 10.1111/j.1524-4725.1992.tb02922.x. [DOI] [PubMed] [Google Scholar]
  29. Werder E. A., Waibel P., Sege D., Flury R. Severe thrombosis during oestrogen treatment for tall stature. Eur J Pediatr. 1990 Mar;149(6):389–390. doi: 10.1007/BF02009654. [DOI] [PubMed] [Google Scholar]
  30. Wessler S. Estrogen-associated thromboembolism. Ann Epidemiol. 1992 Jul;2(4):439–443. doi: 10.1016/1047-2797(92)90093-6. [DOI] [PubMed] [Google Scholar]
  31. Wettenhall H. N., Cahill C., Roche A. F. Tall girls: a survey of 15 years of management and treatment. J Pediatr. 1975 Apr;86(4):602–610. doi: 10.1016/s0022-3476(75)80162-4. [DOI] [PubMed] [Google Scholar]
  32. Whitelaw M. J. Experiences in treating excessive height in girls with cyclic oestradiol valerate. A ten year survey. Acta Endocrinol (Copenh) 1967 Mar;54(3):473–484. doi: 10.1530/acta.0.0540473. [DOI] [PubMed] [Google Scholar]
  33. Zachmann M., Ferrandez A., Můrset G., Prader A. Estrogen treatment of excessively tall girls. Helv Paediatr Acta. 1975 May;30(1):11–30. [PubMed] [Google Scholar]
  34. von Petrykowski W., Schmidt B. High-dose conjugated estrogens do not reduce antithrombin III activity in tall girls. Horm Metab Res. 1983 Aug;15(8):412–412. doi: 10.1055/s-2007-1018741. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES